Brief: Equillium Presents Positive Data From Phase 1B Equalise Study
Brief: Equillium Q3 basic EPS USD -0.11
Brief: Equillium Inc On Oct 5 Co Entered Into An Open Market Sale Agreement With Jefferies Llc
Equillium Inc reports results for the quarter ended in June - Earnings Summary
Brief: Equillium Q2 revenue USD 9.124 million
Brief: Equillium Prepaid In Full All Amounts Due As Of September 30, 2019
Brief: Equillium Reports First Quarter 2023 Financial Results
Equillium Inc reports results for the quarter ended in March - Earnings Summary
Equillium Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Equillium Inc-On April 5, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Equillium Inc reports results for the quarter ended in December - Earnings Summary
Brief: Equillium Reports Fourth Quarter Results
Equillium Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Apollo Global Management, First American Financial, Thomson Reuters
Brief: Equillium Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Equillium Inc - No Termination Fee Will Be Payable By Equillium Or Metacrine In Connection With The Termination Of The Merger Agreement
Brief: Equillium's Partner Biocon Initiates Phase 2 Study Of Itolizumab In Ulcerative Colitis
Equillium gains on selling option to purchase antibody drug rights
Brief: Equillium And Ono Pharmaceutical Announce Exclusive Option And Asset Purchase Agreement For Development And Commercialization Of Itolizumab